UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2019
Commission File Number:001-38746
Taiwan Liposome Company, Ltd.
(Translation of registrant’s name into English)
Taiwan Liposome Company, Ltd.
11F-1, No. 3 Yuanqu Street
Nangang District,
Taipei City, Taiwan 11503
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Departure of Directors
On December 6, 2019, Burrill Life Sciences Capital Fund III, L.P. (the “Director”) resigned as a director of Taiwan Liposome Company, Ltd. (the “Company”) effective immediately due to the Director’s business considerations. The decision was not the result of any disagreement with the Company. The Company is grateful for the Director’s service to the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAIWAN LIPOSOME COMPANY, LTD. | ||||||
Date: December 6, 2019 | By: | /s/ George Yeh | ||||
Name: | George Yeh | |||||
Title: | President |